Clinicopathological Profile of Pure Neuroendocrine Neoplasms of the Esophagus: A South Indian Center Experience

Table 2

Baseline characteristics of esophageal NENs.

Variable	Number (percentage)
Age
<40 years	5 (11.6%)
40–60 years	15 (34.9%)
>60 years	23 (53.5%)
Gender
Male	26 (60.5%)
Female	17 (39.5%)
Symptoms
Dysphagia	38 (88.3%)
Abdominal/retrosternal pain	9 (22.5%)
Loss of weight or loss of appetite	8 (18.6%)
Gastrointestinal bleed	2 (4.6%)
Carcinoid syndrome	0
Performance status
1/2	34 (79%)
3	9 (21%)
Esophagus tumor location
Upper third (15–25 cm from incisor)	1 (2.3%)
Middle third (25–30 cm from incisor)	7 (16.3%)
Lower third, GE junction (30–40 cm from incisor)	35 (81.4%)
Mitotic count and Ki-67 index (WHO, [21])
G1: <2/10 HPF’s; <2%	0
G2: 2–20/10 HPF’s; 3–20%	7 (16.3%)
G3: >20/10 HPF’s; >20%	36 (83.7%)
Disease stage
I	0
II	6 (14%)
III	14 (32.5%)
IV	23 (53.5%)
Treatment received
STAGE II, III (; 46.5%)	mOS = 18.25 m (2.5–60 m)
Upfront surgery (THE/TTE) CT	mOS = 18.5 m (2.5–60 m)
NACT plus surgery	mOs = 15.25 m
Received Chemo/Oct LAR only	mOS = 12 m (6–30 m)
STAGE IV (; 53.5%)	mOS = 6.5 (1.5–32 m)
Cisplatin + etoposide	mOS = 6.5 m (1.5–32 m)
Octreotide LAR	mOS = 16 m
mOS stage II ()	43 m (18–60 m)
mOS stage III ()	12.5 m (6–30 m)